Pharmaceutical company AstraZeneca will be supplying the United States with up to half a million extra doses of its experimental antibody-based COVID-19 therapy, Reuters reported.
The treatment has not been approved by U.S. regulators.
Unlike a vaccine that is intended to prevent a COVID-19 infection, the treatment treats the illness, Reuters reported.
It has shown promise combating the variants of COVID-19, Bloomberg reported.
The drugmaker said the 500,000 additional doses are in addition to the 200,000 doses that were agreed upon in October.
The deal will cost as much as $726 million, Bloomberg reported.
The shipment is contingent on an emergency use approval by the Food and Drug Administration.
The treatment, AZD7442, is in late-stage trials, Reuters reported.
More coronavirus pandemic coverage:
How to find Country Legends
Download the FREE Country Legends 97.1 app now!
Eagles on Tour
Celebrities react to death of singer-actor Aaron Carter
Houston’s Iconic Warehouse Live Relocating to Rise Rooftop in Midtown
Bucs WR Antonio Brown off team after discarding jersey, exiting field
Thanksgiving 2022: Which grocery stores are open, closed on Thanksgiving?
Florida sues realty company and reality-star founder for ‘swindling’ homeowners across U.S.